Insider Buying Stocks
BLCO is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
BAUSCH + LOMB CORP (BLCO) Stock Price & Overview
NYSE:BLCO • CA0717051076
Current stock price
15.72 USD
-0.16 (-1.01%)
At close:
15.72 USD
0 (0%)
After Hours:
The current stock price of BLCO is 15.72 USD. Today BLCO is down by -1.01%. In the past month the price increased by 3.01%. In the past year, price increased by 36.7%.
BLCO Key Statistics
52-Week Range10.83 - 18.915
Current BLCO stock price positioned within its 52-week range.
1-Month Range15.41 - 17.12
Current BLCO stock price positioned within its 1-month range.
- Market Cap
- 5.603B
- P/E
- 31.44
- Fwd P/E
- 19.87
- EPS (TTM)
- 0.50
- Dividend Yield
- N/A
BLCO Stock Performance
Today
-1.01%
1 Week
-2.00%
1 Month
+3.01%
3 Months
-5.87%
Longer-term
6 Months +5.22%
1 Year +36.70%
2 Years +8.12%
3 Years -9.97%
5 Years N/A
10 Years N/A
BLCO Stock Chart
BLCO Stock Screens
BLCO currently appears in the following ChartMill screener lists.
BLCO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLCO. When comparing the yearly performance of all stocks, BLCO is one of the better performing stocks in the market, outperforming 71.56% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BLCO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCO. There are concerns on the financial health of BLCO while its profitability can be described as average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BLCO Earnings
On April 29, 2026 BLCO reported an EPS of 0.08 and a revenue of 1.24B. The company beat EPS expectations (38.35% surprise) and beat revenue expectations (0.16% surprise).
Next Earnings DateN/A
Last Earnings DateApr 29, 2026
PeriodQ1 / 2026
EPS Reported$0.08
Revenue Reported1.244B
EPS Surprise 38.35%
Revenue Surprise 0.16%
BLCO Forecast & Estimates
19 analysts have analysed BLCO and the average price target is 18.74 USD. This implies a price increase of 19.23% is expected in the next year compared to the current price of 15.72.
For the next year, analysts expect an EPS growth of 58.21% and a revenue growth 7.03% for BLCO
Analysts
Analysts71.58
Price Target18.74 (19.21%)
EPS Next Y58.21%
Revenue Next Year7.03%
BLCO Financial Highlights
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS decreased by -19.35% compared to the year before.
Income Statements
Revenue(TTM)5.10B
Net Income(TTM)-360.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.57% | ||
| ROE | -5.58% | ||
| Debt/Equity | 0.78 |
Chartmill High Growth Momentum
EPS Q2Q%28%
Sales Q2Q%9.77%
EPS 1Y (TTM)-19.35%
Revenue 1Y (TTM)6.47%
BLCO Ownership
Ownership
Inst Owners11.25%
Shares356.40M
Float43.57M
Ins Owners0.64%
Short Float %8.52%
Short Ratio8.37
BLCO Industry Overview
BLCO operates in the Health Care Supplies sub-industry within the Health Care sector. This group contains 3 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
23/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
22/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
75%
Outperformed 75% of sub-industries
3 Month Rank
26%
Outperformed 26% of sub-industries
6 Month Rank
2%
Outperformed 2% of sub-industries
Industry Fundamentals & Breadth
- Members
- 3
- New Highs
- 0%
- New Lows
- 33.3%
- Average ROE
- %
- Average Profit Margin
- %
- Average Operating Margin
- 3.7%
- Average P/E
- 31.8
- Average Fwd P/E
- 20.1
- Average Debt/Equity
- 0.8
BLCO Latest News, Press Relases and Analysis
an hour ago - By: Chartmill
BLCO Competitors/Peers
The largest stocks on the US markets in the "Health Care Supplies" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 29.5 | 58.118B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.39 | 12.697B | ||
| COO | COOPER COS INC/THE | 12.43 | 12.31B | ||
| SOLV | SOLVENTUM CORP | 10.25 | 11.707B | ||
| LNTH | LANTHEUS HOLDINGS INC | 15.77 | 5.428B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 16.15 | 3.981B | ||
| ICUI | ICU MEDICAL INC | 14.63 | 3.024B | ||
| HAE | HAEMONETICS CORP/MASS | 11.3 | 2.781B | ||
| XRAY | DENTSPLY SIRONA INC | 8.07 | 2.353B | ||
| NEOG | NEOGEN CORP | 27.54 | 2.033B | ||
| UFPT | UFP TECHNOLOGIES INC | 19.37 | 1.505B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.322B | ||
| AVNS | AVANOS MEDICAL INC | 24.12 | 1.146B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BLCO
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
IPO: 2022-05-06
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13000
Phone: 19082552864
BAUSCH + LOMB CORP / BLCO FAQ
What does BLCO do?
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
What is the stock price of BAUSCH + LOMB CORP today?
The current stock price of BLCO is 15.72 USD. The price decreased by -1.01% in the last trading session.
Does BLCO stock pay dividends?
BLCO does not pay a dividend.
What is the ChartMill rating of BAUSCH + LOMB CORP stock?
BLCO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is BAUSCH + LOMB CORP (BLCO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLCO.
Can you provide the growth outlook for BAUSCH + LOMB CORP?
The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 7.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BAUSCH + LOMB CORP?
BAUSCH + LOMB CORP (BLCO) has a market capitalization of 5.60B USD. This makes BLCO a Mid Cap stock.